Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -638.49% is 93% above its 5-year average of -8720.41%, near the high end of its 5-year range (-14971.93%–-45.66%).
92.12% above its 12-month average of -8105.86%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2025 (2025-06-30): -45.66%.
EBITDA MARGIN
-638.49%
EBITDA MARGIN AVG TTM
-8105.86%
EBITDA MARGIN AVG 3Y
-8517.56%
EBITDA MARGIN AVG 5Y
-8720.41%
EBITDA MARGIN AVG 10Y
-6338.12%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+92.12%
CURRENT VS 3Y AVG
+92.50%
CURRENT VS 5Y AVG
+92.68%
CURRENT VS 10Y AVG
+89.93%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Traws Pharma, Inc.
Market Cap
$7.93M
EBITDA Margin
-638.49%
TTM Avg
-8105.86%
3Y Avg
-8517.56%
5Y Avg
-8720.41%
Market Cap
$7.86M
EBITDA Margin
-144973.96%
TTM Avg
-73136.05%
3Y Avg
-36678.29%
5Y Avg
-29395.87%
Market Cap
$7.95M
EBITDA Margin
-951.52%
TTM Avg
-1801.56%
3Y Avg
-1801.56%
5Y Avg
-1801.56%
Market Cap
$8.08M
EBITDA Margin
-33055.56%
TTM Avg
-18473.68%
3Y Avg
-9547.23%
5Y Avg
-12604.39%
Market Cap
$8.27M
EBITDA Margin
-194787.38%
TTM Avg
-191929.49%
3Y Avg
-133856.30%
5Y Avg
-96317.48%
Market Cap
$8.33M
EBITDA Margin
-65.39%
TTM Avg
-49.20%
3Y Avg
-36.51%
5Y Avg
-25.14%
Market Cap
$8.49M
EBITDA Margin
-334.15%
TTM Avg
-180.95%
3Y Avg
-121.99%
5Y Avg
-121.99%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | $7.93M | -638.49% | -8105.86% | -8517.56% | -8720.41% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.86M | -144973.96% | -73136.05% | -36678.29% | -29395.87% |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.95M | -951.52% | -1801.56% | -1801.56% | -1801.56% |
| GT Biopharma, Inc. (GTBP)vs › | $8.08M | -33055.56% | -18473.68% | -9547.23% | -12604.39% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | N/A | N/A | N/A | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.72M | N/A | N/A | N/A | N/A |
| HeartSciences Inc. (HSCS)vs › | $8.27M | -194787.38% | -191929.49% | -133856.30% | -96317.48% |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.33M | -65.39% | -49.20% | -36.51% | -25.14% |
| DataMEDS AI, Inc. (MEDS)vs › | $8.49M | -334.15% | -180.95% | -121.99% | -121.99% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.29M | 1.07% | 13.21% | 13.21% | 13.21% |
Gross Margin
100.0%
EBITDA Margin
-638.5%
Operating Margin
-640.7%
Net Margin
328.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-06-30 | -45.66% |
| 2024-12-31 | -14971.93% |
| 2024-06-30 | -9300.00% |
| 2023-12-31 | -8444.25% |
| 2023-06-30 | -9504.42% |
| 2022-12-31 | -10060.18% |
| 2022-06-30 | -7296.46% |
| 2021-12-31 | -6854.87% |
| 2021-06-30 | -7730.97% |
| 2020-12-31 | -10179.67% |
| 2020-06-30 | -11536.11% |
| 2019-12-31 | -11634.41% |
| 2019-06-30 | -519.90% |
| 2018-12-31 | -6545.25% |
| 2018-06-30 | -1097.33% |
| 2017-12-31 | -5073.12% |
| 2017-06-30 | -2399.63% |
| 2016-12-31 | -588.65% |
| 2016-06-30 | -345.81% |
| 2015-12-31 | -23.30% |
| 2015-06-30 | -8948.52% |
| 2014-12-31 | -12303.51% |
| 2014-06-30 | -6163.99% |
| 2013-12-31 | -1130.14% |
| 2013-06-30 | -1602.34% |
| 2012-12-31 | -7.04% |
| 2012-06-30 | -4482.30% |
